{"id":"uracil-mustard","rwe":[],"tags":[{"label":"uracil mustard","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"L01AD08","category":"atc"},{"label":"Off-Patent","category":"patent"},{"label":"Active","category":"status"},{"label":"Chronic lymphoid leukemia, disease","category":"indication"},{"label":"Chronic myeloid leukemia","category":"indication"},{"label":"Non-Hodgkin's lymphoma","category":"indication"},{"label":"Polycythemia vera","category":"indication"},{"label":"Approved 1960s","category":"decade"},{"label":"Alkylating Agents","category":"pharmacology"},{"label":"Antineoplastic Agents","category":"pharmacology"},{"label":"Antineoplastic Agents, Alkylating","category":"pharmacology"},{"label":"Noxae","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=URACIL MUSTARD","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:00:25.704220+00:00"},"timeline":{"url":"https://en.wikipedia.org/wiki/Uracil Mustard","method":"deterministic","source":"Wikipedia","rawText":"","confidence":0.8,"sourceType":"wikipedia","retrievedAt":"2026-04-20T02:00:38.897670+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:00:37.416058+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=URACIL MUSTARD","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:00:38.173312+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: DNA inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:00:38.897360+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL1488/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:00:38.788147+00:00"}},"allNames":"uramustin","offLabel":[],"synonyms":["uracil mustard","aminouracil mustard","chlorethaminacil","demethyldopan","desmethyldopan","uracil nitrogen mustard","uramustin","uramustine"],"timeline":[{"date":"1962-09-13","type":"positive","source":"DrugCentral","milestone":"FDA approval"}],"approvals":[{"date":"1962-09-13","orphan":false,"company":"","regulator":"FDA"}],"brandName":"Uramustin","ecosystem":[{"indication":"Chronic lymphoid leukemia, disease","otherDrugs":[{"name":"bendamustine","slug":"bendamustine","company":"Cephalon"},{"name":"chlorambucil","slug":"chlorambucil","company":"Aspen Global Inc"},{"name":"cyclophosphamide","slug":"cyclophosphamide","company":"Baxter Hlthcare"},{"name":"duvelisib","slug":"duvelisib","company":"Verastem Inc"}],"globalPrevalence":null},{"indication":"Chronic myeloid leukemia","otherDrugs":[{"name":"cyclophosphamide","slug":"cyclophosphamide","company":"Baxter Hlthcare"},{"name":"hydroxycarbamide","slug":"hydroxycarbamide","company":"Bristol Myers Squibb"},{"name":"mechlorethamine","slug":"mechlorethamine","company":"Recordati Rare"},{"name":"omacetaxine mepesuccinate","slug":"omacetaxine-mepesuccinate","company":"Ivax Intl"}],"globalPrevalence":480000},{"indication":"Non-Hodgkin's lymphoma","otherDrugs":[{"name":"betamethasone","slug":"betamethasone","company":""},{"name":"betamethasone acetate","slug":"betamethasone-acetate","company":""},{"name":"bleomycin","slug":"bleomycin","company":"Bristol Myers Squibb"},{"name":"carmustine","slug":"carmustine","company":"Emcure Pharms Ltd"}],"globalPrevalence":123507000},{"indication":"Polycythemia vera","otherDrugs":[{"name":"mechlorethamine","slug":"mechlorethamine","company":"Recordati Rare"},{"name":"ropeginterferon alfa-2b","slug":"ropeginterferon-alfa-2b","company":"Pharma Essentia Corporation"},{"name":"ruxolitinib","slug":"ruxolitinib","company":"Incyte Corp"},{"name":"sodium phosphate (32P)","slug":"sodium-phosphate-(32p)","company":"Mallinckrodt"}],"globalPrevalence":2400000}],"mechanism":{"novelty":"First-in-class","modality":"Small Molecule","drugClass":"uracil mustard","explanation":"","oneSentence":"","technicalDetail":"Uramustin exerts its cytotoxic effects through the formation of interstrand DNA cross-links, which prevent DNA replication and transcription, ultimately leading to cell death."},"_wikipedia":{"url":"https://en.wikipedia.org/wiki/Uramustine","title":"Uramustine","extract":"Uramustine (INN) or uracil mustard is a chemotherapy drug which belongs to the class of alkylating agents. It is used in lymphatic malignancies such as non-Hodgkin's lymphoma. It works by damaging DNA, primarily in cancer cells that preferentially take up the uracil due to their need to make nucleic acids during their rapid cycles of cell division. The DNA damage leads to apoptosis of the affected cells. Bone marrow suppression and nausea are the main side effects."},"commercial":{"launchDate":"1962","_launchSource":"DrugCentral (FDA 1962-09-13, )"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/2795","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=URACIL%20MUSTARD","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=URACIL MUSTARD","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://en.wikipedia.org/wiki/Uramustine","fields":["history","overview"],"source":"Wikipedia"},{"id":5,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T16:11:45.023593","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:00:40.773090+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"carmustine","drugSlug":"carmustine","fdaApproval":"1977-03-07","genericCount":11,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"lomustine","drugSlug":"lomustine","fdaApproval":"1976-08-04","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"streptozocin","drugSlug":"streptozocin","fdaApproval":"1982-05-07","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"uracil mustard","indications":{"approved":[{"name":"Chronic lymphoid leukemia, disease","source":"DrugCentral","snomedId":92814006,"regulator":"FDA"},{"name":"Chronic myeloid leukemia","source":"DrugCentral","snomedId":92818009,"regulator":"FDA","usPrevalence":null,"globalPrevalence":480000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (22033323[PMID]_RARECARE surveillance of rare cancers in Europe[REG])"},{"name":"Non-Hodgkin's lymphoma","source":"DrugCentral","snomedId":118601006,"regulator":"FDA","usPrevalence":null,"globalPrevalence":123507000,"prevalenceMethod":"curated","prevalenceSource":"J Insur Med, 2023 (PMID:37725503)"},{"name":"Polycythemia vera","source":"DrugCentral","snomedId":109992005,"regulator":"FDA","usPrevalence":null,"globalPrevalence":2400000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet ([EXPERT]_European Medicines Agency 2014[INST])"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"carmustine","brandName":"carmustine","genericName":"carmustine","approvalYear":"1977","relationship":"same-class"},{"drugId":"lomustine","brandName":"lomustine","genericName":"lomustine","approvalYear":"1976","relationship":"same-class"},{"drugId":"streptozocin","brandName":"streptozocin","genericName":"streptozocin","approvalYear":"1982","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06966700","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-06-30","conditions":["Breast Neoplasms","Triple Negative Breast Neoplasms","HR Low-Positive/HER2-Negative Breast Neoplasms"],"enrollment":2400,"completionDate":"2034-12-29"},{"nctId":"NCT03585465","phase":"PHASE1,PHASE2","title":"Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-03-26","conditions":["Childhood Solid Tumor"],"enrollment":63,"completionDate":"2027-01"},{"nctId":"NCT06797635","phase":"PHASE2","title":"Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-20","conditions":["Breast Neoplasms","Breast Cancer"],"enrollment":372,"completionDate":"2034-12-31"},{"nctId":"NCT06829199","phase":"PHASE2","title":"A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-26","conditions":["Early Triple Negative Breast Cancer"],"enrollment":0,"completionDate":"2031-03-18"},{"nctId":"NCT06291064","phase":"PHASE2","title":"Trial Studying Chemotherapy in Nigerian Women With Triple Negative Breast Cancer","status":"RECRUITING","sponsor":"University of Chicago","startDate":"2025-03-18","conditions":["Triple Negative Breast Cancer"],"enrollment":85,"completionDate":"2032-06"},{"nctId":"NCT06085742","phase":"PHASE2","title":"BRE-08 Phase II Study of CMC Regimen for Early Stage Breast Cancer","status":"RECRUITING","sponsor":"University of Illinois at Chicago","startDate":"2023-11-22","conditions":["Breast Cancer"],"enrollment":25,"completionDate":"2034-09"},{"nctId":"NCT06112379","phase":"PHASE3","title":"A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2023-11-14","conditions":["Breast Cancer"],"enrollment":1902,"completionDate":"2032-09-23"},{"nctId":"NCT04390399","phase":"PHASE2","title":"Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunityBio, Inc.","startDate":"2020-07-21","conditions":["Pancreatic Cancer"],"enrollment":328,"completionDate":"2026-05-31"},{"nctId":"NCT02688803","phase":"PHASE4","title":"Multicentre Study to Determine the Feasibility of Using an Integrated Consent Model to Compare Three Standard of Care Regimens for The Treatment of Triple-Negative Breast Cancer in the Neoadjuvant/Adjuvant Setting (REaCT-TNBC)","status":"TERMINATED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-08-30","conditions":["Breast Cancer"],"enrollment":2,"completionDate":"2017-10"},{"nctId":"NCT06409390","phase":"PHASE2","title":"Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-08-14","conditions":["Metastatic Breast Cancer"],"enrollment":15,"completionDate":"2027-04"},{"nctId":"NCT01358877","phase":"PHASE3","title":"A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-11-08","conditions":["Breast Cancer"],"enrollment":4804,"completionDate":"2024-11-28"},{"nctId":"NCT04443348","phase":"PHASE2","title":"Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Laura M. Spring, MD","startDate":"2020-12-16","conditions":["Triple Negative Breast Cancer","Hormone Receptor Positive (HR+), HER2-negative Breast Cancer","Biopsy-proven, Positive Lymph Node(s)"],"enrollment":120,"completionDate":"2027-08"},{"nctId":"NCT00872625","phase":"PHASE1","title":"Radiation Therapy and Docetaxel Followed by Standard Therapy in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"Centre Antoine Lacassagne","startDate":"2007-04","conditions":["Breast Cancer"],"enrollment":26,"completionDate":"2010-12"},{"nctId":"NCT06245889","phase":"PHASE2","title":"PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2024-05-01","conditions":["Triple Negative Breast Cancer"],"enrollment":30,"completionDate":"2030-06"},{"nctId":"NCT04335669","phase":"PHASE3","title":"NordicTrip, a Translational Study of Preoperative Chemotherapy in TNBC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Lund University Hospital","startDate":"2019-12-20","conditions":["Breast Cancer","Triple Negative Breast Neoplasms"],"enrollment":325,"completionDate":"2035-09"},{"nctId":"NCT01354522","phase":"PHASE3","title":"TAC Versus TCX as Adjuvant Treatment for High-risk Her2-Negative Breast Cancer","status":"COMPLETED","sponsor":"Peking Union Medical College Hospital","startDate":"2011-05","conditions":["Breast Cancer"],"enrollment":204,"completionDate":"2023-12"},{"nctId":"NCT02419495","phase":"PHASE1","title":"Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2015-06-26","conditions":["Advanced Malignant Solid Neoplasm","Clinical Stage III Cutaneous Melanoma AJCC v8","Clinical Stage IV Cutaneous Melanoma AJCC v8","Fallopian Tube Carcinoma","Metastatic Lung Non-Small Cell Carcinoma","Metastatic Malignant Solid Neoplasm","Metastatic Melanoma","Metastatic Renal Cell Carcinoma","Ovarian Carcinoma","Pathologic Stage III Cutaneous Melanoma AJCC v8","Pathologic Stage IIIA Cutaneous Melanoma AJCC v8","Pathologic Stage IIIB Cutaneous Melanoma AJCC v8","Pathologic Stage IIIC Cutaneous Melanoma AJCC v8","Pathologic Stage IIID Cutaneous Melanoma AJCC v8","Pathologic Stage IV Cutaneous Melanoma AJCC v8","Primary Peritoneal Carcinoma","Stage III Lung Cancer AJCC v8","Stage III Renal Cell Cancer AJCC v8","Stage IIIA Lung Cancer AJCC v8","Stage IIIB Lung Cancer AJCC v8","Stage IIIC Lung Cancer AJCC v8","Stage IV Lung Cancer AJCC v8","Stage IV Renal Cell Cancer AJCC v8","Stage IVA Lung Cancer AJCC v8","Stage IVB Lung Cancer AJCC v8","Triple-Negative Breast Carcinoma","Unresectable Lung Non-Small Cell Carcinoma","Unresectable Melanoma","Unresectable Renal Cell Carcinoma"],"enrollment":221,"completionDate":"2024-09-16"},{"nctId":"NCT03169790","phase":"PHASE1,PHASE2","title":"QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":["Non Hodgkin Lymphoma"],"enrollment":0,"completionDate":"2021-12-23"},{"nctId":"NCT03169764","phase":"PHASE1,PHASE2","title":"QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":["Head and Neck Squamous Cell Carcinoma"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT03197584","phase":"PHASE1,PHASE2","title":"QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":["Ovarian Cancer"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT03574649","phase":"PHASE2","title":"QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-06","conditions":["Non Small Cell Lung Cancer"],"enrollment":0,"completionDate":"2018-08-22"},{"nctId":"NCT03563144","phase":"PHASE2","title":"QUILT-3.088: NANT Pancreatic Cancer Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":["Metastatic Pancreatic Cancer"],"enrollment":0,"completionDate":"2022-02-09"},{"nctId":"NCT03169777","phase":"PHASE1,PHASE2","title":"QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-08","conditions":["Colorectal Cancer"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT03175666","phase":"PHASE1,PHASE2","title":"QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":["Triple Negative Breast Cancer"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT03167177","phase":"PHASE1,PHASE2","title":"QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":["Melanoma"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT03169738","phase":"PHASE1,PHASE2","title":"QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-02","conditions":["Non-small Cell Lung Cancer"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT03167164","phase":"PHASE1,PHASE2","title":"QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":["Merkel Cell Carcinoma"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT03197571","phase":"PHASE1,PHASE2","title":"QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2017-12","conditions":["Urothelial Carcinoma"],"enrollment":0,"completionDate":"2021-12-28"},{"nctId":"NCT03554109","phase":"PHASE2","title":"QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-09","conditions":["Triple Negative Breast Cancer (TNBC)"],"enrollment":0,"completionDate":"2022-02-09"},{"nctId":"NCT02299999","phase":"PHASE2","title":"SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"UNICANCER","startDate":"2014-04-07","conditions":["Metastatic Breast Cancer"],"enrollment":1460,"completionDate":"2025-12"},{"nctId":"NCT01954992","phase":"PHASE3","title":"Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer","status":"RECRUITING","sponsor":"Eleison Pharmaceuticals LLC.","startDate":"2014-04","conditions":["Metastatic Pancreatic Adenocarcinoma"],"enrollment":480,"completionDate":"2026-12"},{"nctId":"NCT03997968","phase":"PHASE1,PHASE2","title":"A Phase 1/2 Study of CYT-0851 in B-Cell Malignancies and Advanced Solid Tumors","status":"COMPLETED","sponsor":"Cyteir Therapeutics, Inc.","startDate":"2019-10-09","conditions":["Malignancy","Non-hodgkin Lymphoma","Multiple Myeloma","Breast Cancer","Ovarian Cancer","Soft Tissue Sarcoma","Head and Neck Cancer","DLBCL","Mantle Cell Lymphoma","Follicular Lymphoma","Pancreatic Cancer","CLL","Small Cell Lung Cancer","Squamous Cell Carcinoma of Head and Neck","Triple Negative Breast Cancer"],"enrollment":169,"completionDate":"2024-12-20"},{"nctId":"NCT04534218","phase":"PHASE2","title":"Regorafenib in Combination With Metronomic Chemotherapies, and Low-dose Aspirin in Metastatic Colorectal Cancer","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Besancon","startDate":"2020-10-16","conditions":["Colo-rectal Cancer","Metastatic Cancer"],"enrollment":49,"completionDate":"2023-12-13"},{"nctId":"NCT00798070","phase":"PHASE3","title":"Panther: A Study Comparing Biweekly and Tailored EC-T Versus Three Weekly FEC-T in Breast Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Karolinska University Hospital","startDate":"2007-02","conditions":["Breast Cancer"],"enrollment":2017,"completionDate":"2028-01"},{"nctId":"NCT03329248","phase":"PHASE1,PHASE2","title":"QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2017-11-06","conditions":["Pancreatic Cancer"],"enrollment":6,"completionDate":"2019-11-01"},{"nctId":"NCT03563157","phase":"PHASE1,PHASE2","title":"QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-09-28","conditions":["Colorectal Cancer Metastatic","mCRC"],"enrollment":2,"completionDate":"2019-08-21"},{"nctId":"NCT03009058","phase":"PHASE1,PHASE2","title":"Study of IMM 101 in Combination With Standard of Care in Patients With Metastatic or Unresectable Cancer","status":"TERMINATED","sponsor":"Immodulon Therapeutics Ltd","startDate":"2017-05-31","conditions":["Metastatic Cancer"],"enrollment":2,"completionDate":"2017-08-30"},{"nctId":"NCT03586869","phase":"PHASE1,PHASE2","title":"QUILT-3.080: NANT Pancreatic Cancer Vaccine","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-07-17","conditions":["Pancreatic Cancer"],"enrollment":3,"completionDate":"2019-08-01"},{"nctId":"NCT03387085","phase":"PHASE1,PHASE2","title":"QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-03-19","conditions":["Triple Negative Breast Cancer"],"enrollment":9,"completionDate":"2024-01-16"},{"nctId":"NCT03387111","phase":"PHASE1,PHASE2","title":"QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have Progressed","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2018-01-09","conditions":["Squamous Cell Carcinoma"],"enrollment":4,"completionDate":"2021-01-11"},{"nctId":"NCT03136406","phase":"PHASE1,PHASE2","title":"QUILT-3.039: NANT Pancreatic Cancer Vaccine: Combination Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2017-08-11","conditions":["Pancreatic Cancer"],"enrollment":3,"completionDate":"2019-11-01"},{"nctId":"NCT03387098","phase":"PHASE1,PHASE2","title":"QUILT-3.070:Pancreatic Cancer Vaccine: Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2017-12-28","conditions":["Pancreatic Cancer"],"enrollment":4,"completionDate":"2019-01-15"},{"nctId":"NCT00433420","phase":"PHASE3","title":"Combination Chemotherapy With or Without Fluorouracil and/or Pegfilgrastim in Treating Women With Node-Positive Breast Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy","startDate":"2003-04","conditions":["Breast Cancer"],"enrollment":2000,"completionDate":"2025-12"},{"nctId":"NCT02897700","phase":"PHASE1","title":"A Randomized Trial of Chemotherapy in Surgical Patients With Infiltrating Ductal Carcinoma of Breast","status":"RECRUITING","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2013-01","conditions":["Breast Cancer"],"enrollment":300,"completionDate":"2027-12"},{"nctId":"NCT01996267","phase":"PHASE3","title":"Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2013-12","conditions":["Breast Cancer","HER2 Positive"],"enrollment":437,"completionDate":"2030-12"},{"nctId":"NCT00036868","phase":"PHASE2","title":"Combination Chemotherapy With Trastuzumab in Treating Women With Metastatic Breast Cancer","status":"COMPLETED","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2002-02","conditions":["Breast Cancer"],"enrollment":90,"completionDate":"2010-02"},{"nctId":"NCT02954055","phase":"PHASE2","title":"MEtronomic TrEatment Option in Advanced bReast cAncer","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2017-09-13","conditions":["Breast Cancer"],"enrollment":140,"completionDate":"2022-11-23"},{"nctId":"NCT00630032","phase":"PHASE3","title":"Safety and Efficacy Comparison of Docetaxel and Ixabepilone in Non Metastatic Poor Prognosis Breast Cancer","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2007-09","conditions":["Breast Cancer"],"enrollment":762,"completionDate":"2020-09-03"},{"nctId":"NCT06229067","phase":"PHASE2","title":"Efficacy and Safety of PD-L1 Monoclonal Antibody Combined With Metronomic VEX in Advanced Triple-negative Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-01-19","conditions":["Breast Cancer","Triple Negative Breast Cancer"],"enrollment":182,"completionDate":"2027-01-19"},{"nctId":"NCT04350021","phase":"","title":"Effect of Low Dose Metronomic Chemotherapy in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Vastra Gotaland Region","startDate":"2019-03-01","conditions":["Breast Cancer Metastatic","Chemotherapy Effect"],"enrollment":40,"completionDate":"2023-10-30"},{"nctId":"NCT06154590","phase":"","title":"Anastrozole Adjuvant Trial - Study of Anastrozole Compared to NOLVADEX (Tamoxifen Citrate) for Adjuvant Treatment of Early Breast Cancer Clinical Studies), Adjunct Cytotoxic Chemotherapy and Malignant Joint Tumor","status":"NOT_YET_RECRUITING","sponsor":"DR. DIANE CHISESI NFS. MD. PHD.","startDate":"2024-07","conditions":["Metastatic Breast Cancer","Tumor","Muscle Neoplasms","Chronic Pain"],"enrollment":100,"completionDate":"2026-09"},{"nctId":"NCT00525759","phase":"PHASE2","title":"Investigating the Biological Effects of the Addition of Zoledronic Acid to Pre-operative Chemotherapy in Breast Cancer","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2007-07","conditions":["Breast Cancer"],"enrollment":40,"completionDate":"2010-01"},{"nctId":"NCT01873833","phase":"PHASE2","title":"Capecitabine, Cyclophosphamide, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With HER2-Positive Metastatic Breast Cancer","status":"TERMINATED","sponsor":"University of Southern California","startDate":"2013-07-29","conditions":["HER2-positive Breast Cancer","Recurrent Breast Cancer","Stage IV Breast Cancer"],"enrollment":10,"completionDate":"2021-03-02"},{"nctId":"NCT00665457","phase":"PHASE2","title":"Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery","status":"TERMINATED","sponsor":"University of Nebraska","startDate":"2004-04-15","conditions":["Breast Cancer"],"enrollment":3,"completionDate":"2009-07-31"},{"nctId":"NCT00309478","phase":"PHASE3","title":"Randomized Study Comparing CMF and Goserelin + Tamoxifen in Premenopausal Receptor-positive Patients","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"1990-12","conditions":["Early-stage Breast Cancer"],"enrollment":1099,"completionDate":"2004-06"},{"nctId":"NCT04304352","phase":"PHASE2","title":"Metronomic Oral Chemotherapy With Cyclophosphamide, Capecitabine and Vinorelbine in Metastatic Breast Cancer Patients","status":"UNKNOWN","sponsor":"European Institute of Oncology","startDate":"2011-07-29","conditions":["Advanced Breast Cancer"],"enrollment":162,"completionDate":"2023-12-31"},{"nctId":"NCT00121992","phase":"PHASE3","title":"Docetaxel, Doxorubicin (A), Cyclophosphamide (C) (TAC) vs 5-Fluorouracil, A, C (5FAC) Breast Cancer Adjuvant Treatment","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"1999-07","conditions":["Breast Neoplasms"],"enrollment":1060,"completionDate":"2013-03-06"},{"nctId":"NCT00129935","phase":"PHASE3","title":"EC Followed Docetaxel Versus ET Followed Capecitabine as Adjuvant Chemotherapy for Node Positive Operable Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2004-02","conditions":["Breast Cancer"],"enrollment":1384,"completionDate":"2019-04-04"},{"nctId":"NCT01036087","phase":"PHASE2","title":"Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2010-11","conditions":["Breast Cancer"],"enrollment":47,"completionDate":"2022-08-09"},{"nctId":"NCT02099188","phase":"PHASE2","title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Inoperable Patients","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2013-11","conditions":["Unresectable Sinonasal Tumors"],"enrollment":27,"completionDate":"2024-01"},{"nctId":"NCT02099175","phase":"PHASE2","title":"Multidisciplinary Approach for Poor Prognosis Sinonasal Tumors in Operable Patients","status":"UNKNOWN","sponsor":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","startDate":"2013-11","conditions":["Sinonasal Tumors"],"enrollment":41,"completionDate":"2024-01"},{"nctId":"NCT00129389","phase":"PHASE3","title":"FAC Versus FAC Plus Weekly Paclitaxel as Adjuvant Treatment of Node Negative High Risk Breast Cancer Patients","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"2003-09-19","conditions":["Breast Cancer"],"enrollment":1925,"completionDate":"2013-10-01"},{"nctId":"NCT00129922","phase":"PHASE3","title":"Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer","status":"COMPLETED","sponsor":"Spanish Breast Cancer Research Group","startDate":"1999-11","conditions":["Breast Cancer"],"enrollment":1289,"completionDate":"2007-12"},{"nctId":"NCT00773695","phase":"PHASE2","title":"A Study of Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-11-07","conditions":["Breast Cancer"],"enrollment":150,"completionDate":"2022-11-09"},{"nctId":"NCT01779050","phase":"PHASE2","title":"Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Disseminated Tumor Cells","status":"TERMINATED","sponsor":"Washington University School of Medicine","startDate":"2013-12-19","conditions":["Breast Neoplasms"],"enrollment":7,"completionDate":"2021-09-01"},{"nctId":"NCT03085914","phase":"PHASE1,PHASE2","title":"A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723)","status":"COMPLETED","sponsor":"Incyte Corporation","startDate":"2017-05-02","conditions":["Solid Tumor"],"enrollment":70,"completionDate":"2020-07-13"},{"nctId":"NCT00087178","phase":"PHASE3","title":"Comparison of Two Combination Chemotherapy Regimens in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2004-05","conditions":["Breast Cancer"],"enrollment":2722,"completionDate":"2016-05"},{"nctId":"NCT01966471","phase":"PHASE3","title":"A Study of Trastuzumab Emtansine (Kadcyla) Plus Pertuzumab (Perjeta) Following Anthracyclines in Comparison With Trastuzumab (Herceptin) Plus Pertuzumab and a Taxane Following Anthracyclines as Adjuvant Therapy in Participants With Operable HER2-Positive Primary Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-01-31","conditions":["Breast Cancer"],"enrollment":1846,"completionDate":"2021-06-04"},{"nctId":"NCT03518242","phase":"PHASE1","title":"Molecular Profile of Breast Cancer in Ugandan Patients With Stage IIB-III Breast Cancer","status":"COMPLETED","sponsor":"Fred Hutchinson Cancer Center","startDate":"2018-06-06","conditions":["Breast Cancer Female","Anatomic Stage IIB Breast Cancer AJCC v8","Anatomic Stage III Breast Cancer AJCC v8","Anatomic Stage IIIA Breast Cancer AJCC v8","Anatomic Stage IIIB Breast Cancer AJCC v8","Anatomic Stage IIIC Breast Cancer AJCC v8","Invasive Breast Carcinoma","Prognostic Stage IIB Breast Cancer AJCC v8","Prognostic Stage III Breast Cancer AJCC v8","Prognostic Stage IIIA Breast Cancer AJCC v8","Prognostic Stage IIIB Breast Cancer AJCC v8","Prognostic Stage IIIC Breast Cancer AJCC v8"],"enrollment":100,"completionDate":"2022-05-04"},{"nctId":"NCT02897050","phase":"PHASE2","title":"Trial of Neoadjuvant Docetaxel ± Metronomic Capecitabine/CTX Followed by FEC in Women With Operable Triple Negative Breast Cancer","status":"SUSPENDED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-09","conditions":["Breast Cancer"],"enrollment":170,"completionDate":"2024-09"},{"nctId":"NCT02400567","phase":"PHASE2","title":"Efficacy of Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2015-01","conditions":["Neoadjuvant Operable Breast Cancer"],"enrollment":125,"completionDate":"2020-09"},{"nctId":"NCT04389073","phase":"PHASE2","title":"Safety and Efficacy of Toripalimab in HER2- Metastatic Breast Cancer Patients Treated With Metronomic Vinorelbine","status":"UNKNOWN","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2020-04-01","conditions":["Metastatic Breast Cancer"],"enrollment":138,"completionDate":"2023-12-31"},{"nctId":"NCT05131893","phase":"","title":"Neoadjuvant Treatment of Breast Cancer","status":"NOT_YET_RECRUITING","sponsor":"National Institute of Oncology, Hungary","startDate":"2022-03","conditions":["Breast Cancer"],"enrollment":300,"completionDate":"2031-12"},{"nctId":"NCT02742051","phase":"PHASE2","title":"A Trial of Neoadjuvant Everolimus Plus Letrozole Versus FEC in Women With ER-positive, HER2-negative Breast Cancer","status":"COMPLETED","sponsor":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","startDate":"2016-06","conditions":["Breast Cancer"],"enrollment":40,"completionDate":"2020-03-14"},{"nctId":"NCT01593020","phase":"PHASE2","title":"Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2012-08-03","conditions":["Breast Cancer"],"enrollment":54,"completionDate":"2020-11-04"},{"nctId":"NCT02132949","phase":"PHASE2","title":"A Study Evaluating Pertuzumab (Perjeta) Combined With Trastuzumab (Herceptin) and Standard Anthracycline-based Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced, Inflammatory, or Early-stage Breast Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2014-07-14","conditions":["Breast Cancer"],"enrollment":401,"completionDate":"2020-08-25"},{"nctId":"NCT01220128","phase":"PHASE2","title":"Evaluation of an Anti-cancer Immunotherapy Combined With Standard Neoadjuvant Treatment in Patients With WT1-positive Primary Invasive Breast Cancer","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2011-04-11","conditions":["Neoplasms, Breast"],"enrollment":66,"completionDate":"2014-11-14"},{"nctId":"NCT00365417","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2006-08","conditions":["Breast Cancer"],"enrollment":45,"completionDate":"2009-11"},{"nctId":"NCT03563170","phase":"PHASE1,PHASE2","title":"QUILT-3.072: NANT Hepatocellular Carcinoma (HCC) Vaccine","status":"WITHDRAWN","sponsor":"ImmunityBio, Inc.","startDate":"2018-05-25","conditions":["Hepatocellular Carcinoma Non-resectable","Hepatocellular Carcinoma Recurrent"],"enrollment":0,"completionDate":"2019-08-23"},{"nctId":"NCT00309569","phase":"PHASE3","title":"Randomized Study Comparing Pre- and Postoperative vs. Conventional Adjuvant Treatment in Receptor-negative Patients","status":"COMPLETED","sponsor":"Austrian Breast & Colorectal Cancer Study Group","startDate":"1991-10","conditions":["Early Stage Breast Cancer"],"enrollment":429,"completionDate":"2000-09"},{"nctId":"NCT00014222","phase":"PHASE3","title":"Combination Chemotherapy With or Without Colony-stimulating Factors in Treating Women With Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2000-12-04","conditions":["Breast Cancer"],"enrollment":2104,"completionDate":"2014-03-17"},{"nctId":"NCT00625898","phase":"PHASE3","title":"BETH Study: Treatment of HER2 Positive Breast Cancer With Chemotherapy Plus Trastuzumab vs Chemotherapy Plus Trastuzumab Plus Bevacizumab","status":"TERMINATED","sponsor":"NSABP Foundation Inc","startDate":"2008-04","conditions":["Breast Cancer"],"enrollment":3509,"completionDate":"2014-07"},{"nctId":"NCT00003086","phase":"PHASE1,PHASE2","title":"Repeated Bone Marrow Transplantation in Treating Women With Advanced Breast Cancer","status":"TERMINATED","sponsor":"Louisiana State University Health Sciences Center Shreveport","startDate":"1997-03","conditions":["Breast Cancer"],"enrollment":12,"completionDate":"2001-01-28"},{"nctId":"NCT00510367","phase":"EARLY_PHASE1","title":"Primary Breast Cancer Occurring Concomitant With Pregnancy","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2001-08-07","conditions":["Breast Cancer","Pregnancy"],"enrollment":61,"completionDate":"2020-07-08"},{"nctId":"NCT04031703","phase":"PHASE3","title":"Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2011-01-01","conditions":["Breast Cancer"],"enrollment":647,"completionDate":"2016-04-20"},{"nctId":"NCT00002542","phase":"PHASE3","title":"Tamoxifen in Treating Women With High-Risk Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1993-07-20","conditions":["Breast Cancer"],"enrollment":672,"completionDate":"2011-01-11"},{"nctId":"NCT01855828","phase":"PHASE2","title":"Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer","status":"COMPLETED","sponsor":"Yale University","startDate":"2013-09","conditions":["Her2-Positive Breast Cancer"],"enrollment":50,"completionDate":"2018-08"},{"nctId":"NCT02879513","phase":"PHASE3","title":"Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy","status":"UNKNOWN","sponsor":"RenJi Hospital","startDate":"2014-01","conditions":["Invasive Ductal Breast Cancer","Tubular Breast Cancer","Mucinous Breast Cancer","Inflammatory Breast Cancer"],"enrollment":290,"completionDate":"2022-12"},{"nctId":"NCT04127019","phase":"PHASE3","title":"Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)","status":"COMPLETED","sponsor":"Fudan University","startDate":"2010-06-01","conditions":["Primary Breast Cancer"],"enrollment":2079,"completionDate":"2017-06-15"},{"nctId":"NCT02280694","phase":"PHASE2","title":"Low Dose Metronomic Poly-chemotherapy for Metastatic CRC","status":"COMPLETED","sponsor":"HaEmek Medical Center, Israel","startDate":"2015-01","conditions":["Colorectal Cancer"],"enrollment":45,"completionDate":"2019-12"},{"nctId":"NCT00820547","phase":"PHASE2","title":"Efficacy and Tolerance Study of Bevacizumab in Her2- Inflammatory Breast Cancer Patients","status":"COMPLETED","sponsor":"UNICANCER","startDate":"2009-01","conditions":["Breast Cancer"],"enrollment":100,"completionDate":"2019-09"},{"nctId":"NCT02115204","phase":"PHASE3","title":"4 x Epirubicin, Cyclophosphamide, Followed by 4 x Docetaxel Versus 6 x CMF / 6 x CEF","status":"COMPLETED","sponsor":"West German Study Group","startDate":"2000-06","conditions":["Breast Cancer"],"enrollment":2011,"completionDate":"2010-08"},{"nctId":"NCT01869192","phase":"PHASE2","title":"Phase II Trial for Large ER-Negative Breast Cancers","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2003-03-05","conditions":["Malignant Neoplasm of Female Breast"],"enrollment":72,"completionDate":"2010-08-21"},{"nctId":"NCT02506777","phase":"PHASE2","title":"Neoadjuvant FDC With Melatonin or Metformin for Locally Advanced Breast Cancer.","status":"UNKNOWN","sponsor":"N.N. Petrov National Medical Research Center of Oncology","startDate":"2015-07","conditions":["Breast Cancer"],"enrollment":96,"completionDate":"2020-08"},{"nctId":"NCT02995772","phase":"PHASE3","title":"Neoadjuvant Hormonal Therapy Compared to Neoadjuvant Chemotherapy in Stage IIIB/C and IV Breast Cancer Patients","status":"COMPLETED","sponsor":"Dharmais National Cancer Center Hospital","startDate":"2011-11","conditions":["Breast Cancer"],"enrollment":122,"completionDate":"2018-11"},{"nctId":"NCT01131195","phase":"PHASE3","title":"Metronomic Therapy in Metastatic Breast Cancer.","status":"COMPLETED","sponsor":"Swiss Cancer Institute","startDate":"2010-07-19","conditions":["Breast Cancer"],"enrollment":139,"completionDate":"2018-02-28"},{"nctId":"NCT03925233","phase":"","title":"Breast Cancer Treatment Based on Organ-like Culture","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2019-01-02","conditions":["Breast Cancer Organoids"],"enrollment":300,"completionDate":"2021-12-15"},{"nctId":"NCT03888677","phase":"PHASE3","title":"Dose-adjusted Adjuvant FEC Compared to Standard FEC for Breast Cancer","status":"COMPLETED","sponsor":"Henrik Lindman","startDate":"2001-02","conditions":["Breast Cancer"],"enrollment":1535,"completionDate":"2014-07"},{"nctId":"NCT01891227","phase":"PHASE2","title":"Capecitabine + Bendamustine in Women With Pretreated Locally Advanced or Metastatic Her2-negative Breast Cancer","status":"COMPLETED","sponsor":"Arbeitsgemeinschaft medikamentoese Tumortherapie","startDate":"2013-08-09","conditions":["Breast Cancer"],"enrollment":40,"completionDate":"2018-03-15"},{"nctId":"NCT00301925","phase":"PHASE3","title":"Combination Chemotherapy in Treating Patients With Early Stage Breast Cancer That Has Been Removed By Surgery","status":"UNKNOWN","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2005-12-16","conditions":["Breast Cancer"],"enrollment":4400,"completionDate":"2024-09"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"_patentsChecked":true,"crossReferences":{"NUI":"N0000146436","MMSL":"3099","NDDF":"002634","UNII":"W7KQ46GJ8U","VUID":"4018098","CHEBI":"CHEBI:9884","VANDF":"4018098","INN_ID":"1351","RXNORM":"10996","UMLSCUI":"C0041920","chemblId":"CHEMBL1488","ChEMBL_ID":"CHEMBL1488","KEGG_DRUG":"D06265","DRUGBANK_ID":"DB00791","PUBCHEM_CID":"6194","SNOMEDCT_US":"17243005","IUPHAR_LIGAND_ID":"7621","MESH_DESCRIPTOR_UI":"D014499"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":80,"therapeuticAreas":["Oncology"],"atcClassification":{"source":"DrugCentral","atcCode":"L01AD08","allCodes":["L01AD08"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1962","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"1962-09-13T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:00:40.773090+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}